期刊文献+

小肠细菌过度生长诊断和治疗研究进展 被引量:5

Progress in diagnosis and treatment of small intestinal bacterial overgrowth
下载PDF
导出
摘要 小肠细菌过度生长(small intestinal bacterial overgrowth,SIBO)是由多种因素引起的小肠内细菌的数量和/或种类发生变化而表现为营养吸收不良、腹泻、腹胀及小肠动力异常等症状的临床综合征。近端小肠抽吸液培养法被认为是诊断SIBO的金标准,而呼气试验因其安全、无创性被广泛应用于临床,但有效性不断受到质疑。气敏胶囊技术和高通量测序技术的发展为检测SIBO提供了新方法。此外,SIBO临床症状的非特异性及诊断标准的不统一,使SIBO的治疗存在挑战。鉴于此,本文对SIBO的诊断和治疗方面的研究进展作一综述。 Small intestinal bacterial overgrowth(SIBO)is a clinical syndrome in which the number and/or type of bacteria in the small intestine changes due to various factors and manifests as symptoms of malnutrition,diarrhea,bloating,and small bowel motility.The proximal small intestinal aspiration culture method is considered to be the gold standard for diagnosis of SIBO,and the breath test is widely used clinically because of its safety and non-invasiveness,but it is constantly being questioned.The development of gas-sensitive capsules and high-throughput sequencing technology have provided new means to detect SIBO.In addition,the non-specific clinical symptoms and inconsistent diagnostic criteria of SIBO make SIBO treatment challenging.In view of this,this article reviewed the research progress in the diagnosis and treatment of SIBO.
作者 严明 李小峰 YAN Ming;LI Xiaofeng(Shanxi Medical University,Taiyuan 030000,China)
机构地区 山西医科大学
出处 《胃肠病学和肝病学杂志》 CAS 2020年第11期1301-1304,共4页 Chinese Journal of Gastroenterology and Hepatology
基金 国家自然科学基金(81871295)。
关键词 小肠细菌过度生长 诊断 治疗 呼气试验 Small intestinal bacterial overgrowth Diagnosis Therapy Breath test
  • 相关文献

参考文献1

二级参考文献30

  • 1Qin J,Li R,Raes J,et al.A human gut microbial gene catalogue established by metagenomic sequencing[J].Nature,2010,464 (7285):59-65.
  • 2Arumugam M,Raes J,Pelletier E,et al.Enterotypes of the human gut microbiome[J].Nature,2011,473(7346):174-180.
  • 3Claesson M J,Cusack S,OSullivan O,et al.Composition,variability,and temporal stability of the intestinal microbiota of the elderly[J].Proc Natl Acad Sci U S A,2011,108 Suppl 1:4586-4591.
  • 4Shanahan F.The colonic microbiota in health and disease[J].Curr Opin Gastroenterol,2013,29(1):49-54.
  • 5Faith JJ,McNulty NP,Rey FE,et al.Predicting a human gut microbiota's response to diet in gnotobiotic mice[J].Science,2011,333(6038):101-104.
  • 6Sanders ME,Levy DD.The science and regulations of probiotic food and supplement product labeling[J].Ann N Y Acad Sci,2011,1219Suppl 1:E1-E23.
  • 7OShea EF,Cotter PD,Stanton C,et al.Production of bioactive substances by intestinal bacteria as a basis for explaining probiotic mechanisms:bacteriocins and conjugated linoleic acid[J].Int J Food Microbiol,2012,152(3):189-205.
  • 8Sanders ME,Akkermans LM,Hailer D,et al.Safety assessment of probiotics for human use[J].Gut Microbes,2010,1(3):164-185.
  • 9Whelan K,Myers CE.Safety of probiotics in patients receiving nutritional support:a systematic review of case reports,randomized controlled trials,and nonrandomized trials[J].Am J Clin Nutr,2010,91 (3):687-703.
  • 10Besselink MG,van Santvoort HC,Buskens E,et al.Probiotic prophylaxis in predicted severe acute pancreatitis:a randomised,doubleblind,placebo-controlled trial[J].Lancet,2008,371 (9613):651-659.

共引文献14

同被引文献67

引证文献5

二级引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部